Top

Osteoporosis International

Published in:

01-05-2020 | Spinal Muscular Atrophy | Short Communication

Intravenous bisphosphonate therapy in children with spinal muscular atrophy

Authors: N. Nasomyont, L.N. Hornung, H. Wasserman

Published in: Osteoporosis International | Issue 5/2020

Abstract

Summary

This is the first report on safety and efficacy of intravenous bisphosphonates (IV BP) for treatment of disuse osteoporosis and low bone mineral density (BMD) in children with spinal muscular atrophy (SMA). IV BP appears to be safe and effective in fracture rate reduction. However, caution is necessary given the occurrence of an atypical femur fracture.

Introduction

Children with SMA are at high risk for fragility fractures and low BMD. IV BP have been used for treatment of disuse osteoporosis in pediatrics. However, safety and efficacy of IV BP in the SMA population has not been reported.

Methods

Retrospective chart review of IV BP for treatment of disuse osteoporosis and low BMD in children with SMA at a tertiary pediatric center from 2010 to 2018

Results

Eight patients (50% female; 75% SMA type 1; median age at first infusion 6.7 years) receiving a total of 39 infusions (54% pamidronate, 46% zoledronic acid) were included in this report. Acute phase reactions occurred following 38% and 3% of initial and subsequent infusions, respectively. BMD trended toward improvement at 1 year post-treatment. Among six patients who had > 2 years of follow-up, fracture rate decreased from 1.4 to 0.1 fracture/year. An atypical femur fracture was observed in one patient.

Conclusion

These findings suggest that in children with SMA, IV BP therapy appears to be safe with minimal acute side effects and effective to reduce fracture rate. Caution is still needed given the occurrence of an atypical femur fracture in SMA population.

Michelson D, Ciafaloni E, Ashwal S, Lewis E, Narayanaswami P, Oskoui M et al (2018) Evidence in focus: nusinersen use in spinal muscular atrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 91(20):923–933CrossRef

Vai S, Bianchi ML, Moroni I, Mastella C, Broggi F, Morandi L, Arnoldi MT, Bussolino C, Baranello G (2015) Bone and spinal muscular atrophy. Bone. 79:116–120CrossRef

Shanmugarajan S, Tsuruga E, Swoboda KJ, Maria BL, Ries WL, Reddy SV (2009) Bone loss in survival motor neuron (Smn(-/-) SMN2) genetic mouse model of spinal muscular atrophy. J Pathol 219(1):52–60CrossRef

Wasserman HM, Hornung LN, Stenger PJ, Rutter MM, Wong BL, Rybalsky I, Khoury JC, Kalkwarf HJ (2017) Low bone mineral density and fractures are highly prevalent in pediatric patients with spinal muscular atrophy regardless of disease severity. Neuromuscul Disord 27(4):331–337CrossRef

Vestergaard P, Glerup H, Steffensen BF, Rejnmark L, Rahbek J, Moseklide L (2001) Fracture risk in patients with muscular dystrophy and spinal muscular atrophy. J Rehabil Med 33(4):150–155CrossRef

Fujak A, Kopschina C, Forst R, Gras F, Mueller LA, Forst J (2010) Fractures in proximal spinal muscular atrophy. Arch Orthop Trauma Surg 130(6):775–780CrossRef

Khatri IA, Chaudhry US, Seikaly MG, Browne RH, Iannaccone ST (2008) Low bone mineral density in spinal muscular atrophy. J Clin Neuromuscul Dis 10(1):11–17CrossRef

Kinali M, Banks LM, Mercuri E, Manzur AY, Muntoni F (2004) Bone mineral density in a paediatric spinal muscular atrophy population. Neuropediatrics. 35(6):325–328CrossRef

Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M et al (2018) Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord 28(2):103–115CrossRef

10.

Gordon CM, Leonard MB, Zemel BS (2014) International Society for Clinical D. 2013 Pediatric Position Development Conference: executive summary and reflections. J Clin Densitom 17(2):219–224CrossRef

11.

Ardeshirpour L, Cole DE, Carpenter TO (2007) Evaluation of bone and mineral disorders. Pediatr Endocrinol Rev 5(Suppl 1):584–598PubMed

12.

Henderson RC, Lark RK, Newman JE, Kecskemthy H, Fung EB, Renner JB, Harcke HT (2002) Pediatric reference data for dual X-ray absorptiometric measures of normal bone density in the distal femur. AJR Am J Roentgenol 178(2):439–443CrossRef

13.

Zemel BS, Stallings VA, Leonard MB, Paulhamus DR, Kecskemethy HH, Harcke HT, Henderson RC (2009) Revised pediatric reference data for the lateral distal femur measured by Hologic Discovery/Delphi dual-energy X-ray absorptiometry. J Clin Densitom 12(2):207–218CrossRef

14.

Bachrach SJ, Kecskemethy HH, Harcke HT, Hossain J (2010) Decreased fracture incidence after 1 year of pamidronate treatment in children with spastic quadriplegic cerebral palsy. Dev Med Child Neurol 52(9):837–842CrossRef

15.

Sees JP, Sitoula P, Dabney K, Holmes L Jr, Rogers KJ, Kecskemethy HH et al (2016) Pamidronate treatment to prevent reoccurring fractures in children with cerebral palsy. J Pediatr Orthop 36(2):193–197CrossRef

16.

Poruk KE, Davis RH, Smart AL, Chisum BS, Lasalle BA, Chan GM, Gill G, Reyna SP, Swoboda KJ (2012) Observational study of caloric and nutrient intake, bone density, and body composition in infants and children with spinal muscular atrophy type I. Neuromuscul Disord 22(11):966–973CrossRef

17.

Ozel S, Switzer L, Macintosh A, Fehlings D (2016) Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: an update. Dev Med Child Neurol 58(9):918–923CrossRef

18.

Nasomyont N, Hornung LN, Gordon CM, Wasserman H (2019) Outcomes following intravenous bisphosphonate infusion in pediatric patients: a 7-year retrospective chart review. Bone. 121:60–67CrossRef

19.

Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25(11):2267–2294CrossRef

20.

Boyce AM, Collins MT, Tosi LL, Gafni RI (2017) A subtrochanteric femoral stress fracture following bisphosphonate treatment in an adolescent girl. Horm Res Paediatr 87(1):69–72CrossRef

21.

Trejo P, Fassier F, Glorieux FH, Rauch F (2017) Diaphyseal femur fractures in osteogenesis imperfecta: characteristics and relationship with bisphosphonate treatment. J Bone Miner Res 32(5):1034–1039CrossRef

Title: Intravenous bisphosphonate therapy in children with spinal muscular atrophy
Authors: N. Nasomyont
L.N. Hornung
H. Wasserman
Publication date: 01-05-2020
Publisher: Springer London
Keywords: Spinal Muscular Atrophy
Bisphosphonate
Osteoporosis
Osteoporosis
Pediatrics
Zoledronic Acid
Published in: Osteoporosis International / Issue 5/2020
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-019-05227-9

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Intravenous bisphosphonate therapy in children with spinal muscular atrophy

Abstract

Summary

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2020

Increased rate of reoperation in atypical femoral fractures is related to patient characteristics and not fracture type. A nationwide cohort study

Modification of the RANKL-RANK-binding site for the immunotherapeutic treatment of osteoporosis

Comparison of multimedia and printed patient education tools for patients with osteoporosis: a 6-month randomized controlled trial

Higher fracture prevalence and smaller bone size in patients with hEDS/HSD—a prospective cohort study

Incidental bilateral calcaneal fractures following overground walking with a wearable robotic exoskeleton in a wheelchair user with a chronic spinal cord injury: is zero risk possible?

Analysis of mortality after hip fracture on patient, hospital, and regional level in Germany